Verastem (VSTM) News
NASDAQ: VSTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
6.33-0.53 (-7.73%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VSTM news summary
We found 13 recent headlines mentioning Verastem (VSTM): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. VSTM is making an outsized move today, down 7.73% at $6.33, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Verastem (VSTM) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Verastem headlines
- Verastem (VSTM) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Verastem expects october financing and CO-PACK revenue to fund operations into first half of 2028Seeking Alpha
- Verastem Non-GAAP EPS of -$0.72 misses by $0.28, revenue of $24.01M misses by $2.07MSeeking Alpha
- Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business UpdatesBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial…Business Wire
- Verastem Consensus Price Target Increased by 17.42% to $17.57The average one-year price target for Verastem (NASDAQCM:VSTM) (DB:2VSA) has been revised to $17.57 / share. This is an increase of 17.42% from the prior estimate of $14.96 dated September 29, 2026.…Nasdaq
- Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the…Business Wire
- Why is Verastem stock surging today?Investing.com
- Verastem Oncology Prices $250 Mln Stock, Warrant Offering; Pre-market Shares Up(RTTNews) - Biopharmaceutical company Verastem Oncology (VSTM), announced on Wednesday that it has priced an underwritten offering of 30.94 million shares at $8 each and pre-funded warrants for 0.31…Nasdaq
- Verastem Reports VS-7375 Data, Prices $250M Offering And Names New CEO; Shares Up In Premarket(RTTNews) - Verastem Oncology (VSTM) reported positive responses to its investigational KRAS G12D inhibitor VS-7375 across pancreatic, lung and colorectal cancers in its Phase 1/2 trial. The…NasdaqVSTM, ET
- Verastem Oncology jumps after pricing $250M securities offeringSeeking Alpha
- Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength…NasdaqGMAB, VSTM
- Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue EstimatesRoyalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqRPRX, VSTM
- Guardant Health (GH) Reports Q2 Loss, Tops Revenue EstimatesGuardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqGH, VSTM